Compare PAHC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | OCS |
|---|---|---|
| Founded | 1946 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2014 | N/A |
| Metric | PAHC | OCS |
|---|---|---|
| Price | $52.26 | $28.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $34.33 | ★ $39.57 |
| AVG Volume (30 Days) | 297.5K | ★ 336.1K |
| Earning Date | 02-04-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 373.98 | N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $1,464,325,000.00 | $991,999.00 |
| Revenue This Year | $15.34 | $14.53 |
| Revenue Next Year | $3.28 | $691.13 |
| P/E Ratio | $23.12 | ★ N/A |
| Revenue Growth | ★ 32.39 | N/A |
| 52 Week Low | $16.16 | $14.00 |
| 52 Week High | $56.30 | $29.36 |
| Indicator | PAHC | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 72.49 | 65.31 |
| Support Level | $50.94 | $27.30 |
| Resistance Level | $52.89 | $29.10 |
| Average True Range (ATR) | 2.26 | 1.25 |
| MACD | 1.04 | -0.16 |
| Stochastic Oscillator | 77.30 | 74.19 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.